Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window An analysis ...

Pfizer Ltd has announced that the Scottish Medicines Consortium (SMC) has accepted Talzenna (talazoparib) in combination with ...

For patients with metastatic castration-resistant prostate cancer (mCRPC) unselected for homologous recombination repair (HRR) gene alterations, talazoparib (TALA) + enzalutamide (ENZA ...

Adding talazoparib to enzalutamide led to a statistically significant and clinically meaningful improvement in overall survival in patients with metastatic castration-resistant prostate cancer ...

The Scottish Medicines Consortium has approved two new drugs for use with patients via the NHS. Two new medicines have been ...

Among patients with metastatic castration-resistant prostate cancer (mCRPC), new final overall survival (OS) data from the TALAPRO-2 trial confirm that the combination of Talzenna (talazoparib) plus ...

TALAPRO-2 showed talazoparib and enzalutamide reduced death risk in mCRPC, effective across HRR gene alterations, highlighting the need for next-generation sequencing. STOPCAP meta-analysis found ...

TWO new medicines have been approved to help treat prostate and liver cancer patients in Scotland. The Scottish Medicines ...

Talazoparib (known under the brand name Talzenna), used together with enzalutamide, was accepted for the treatment of adults with prostate cancer. Its approval has been praised for offering ...

SAN FRANCISCO -- Adding talazoparib (Talzenna) to enzalutamide (Xtandi) as initial treatment for metastatic castration-resistant prostate cancer (CRPC) prolonged survival, new analyses from the ...